Evogene(EVGN) - 2020 Q4 - Earnings Call Presentation

Evogene's Vision and Technology - Evogene aims to revolutionize life-science product discovery and development using computational biology technologies[5, 75] - The company utilizes a Computational Predictive Biology (CPB) platform, incorporating scientific understanding, big data, and AI[12, 75] - The CPB platform has three engines: MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements)[75] Business Model and Subsidiaries - Evogene employs a dual business model: product development through collaborations and through subsidiaries[19, 22, 76] - The company has four main subsidiaries: Biomica (human microbiome therapeutics), Canonic (medical cannabis), AgPlenus (ag-chemicals), and Lavie Bio (ag-biologicals)[47, 76] - Evogene holds 90% of Biomica, 100% of Canonic, 98% of AgPlenus, and 72% of Lavie Bio[47] Subsidiary Pipeline Highlights - Biomica's immuno-oncology program is in the pre-clinical stage, targeting a market expected to reach $243 billion by 2026[50] - Canonic is developing MetaYield products for the medical cannabis market, which is expected to reach $25.6 billion by 2024[57] - AgPlenus has a novel MoA herbicide in the 'Lead' stage, targeting a herbicide market expected to reach $34 billion by 2022[61, 63] - Lavie Bio's bio-insecticides addressable market size is $1.5 billion[67] Financial Status - As of December 31, 2020, Evogene had a consolidated cash position of approximately $48.2 million, with around $13 million allocated to Lavie Bio[91] - The estimated net cash usage for 2021, excluding Lavie Bio, is projected to be between $20 million and $22 million[91]